ZONAL DRUG DELIVERY DEVICE AND METHOD
First Claim
1. An ocular implant for treating an eye, comprising:
- an elongate member having a proximal end with at least one inflow port, a distal end with at least one outflow port, and a longitudinal, internal lumen extending through the elongate member, wherein the distal end of the elongate member is in fluid communication with the suprachoroidal space such that the proximal end of the elongate member remains in fluid communication with the anterior chamber when the elongate member is implanted in the eye; and
at least one polymeric film surrounding at least a portion of the elongate member, the film comprising a first drug delivery zone embedded with a first drug, wherein the first drug diffuses from the polymeric film over time into the eye at a first anatomical location.
1 Assignment
0 Petitions
Accused Products
Abstract
Disclosed herein are ocular implants for treating an eye and methods of implantation including an elongate member having a proximal end with at least one inflow port, a distal end with at least one outflow port, and a longitudinal, internal lumen extending through the elongate member. The distal end of the elongate member is in fluid communication with the suprachoroidal space such that the proximal end of the elongate member remains in fluid communication with the anterior chamber when the elongate member is implanted in the eye. At least one polymeric film surrounds at least a portion of the elongate member, the film comprising a first drug delivery zone embedded with a first drug, wherein the first drug diffuses from the polymeric film over time into the eye at a first anatomical location.
-
Citations
13 Claims
-
1. An ocular implant for treating an eye, comprising:
-
an elongate member having a proximal end with at least one inflow port, a distal end with at least one outflow port, and a longitudinal, internal lumen extending through the elongate member, wherein the distal end of the elongate member is in fluid communication with the suprachoroidal space such that the proximal end of the elongate member remains in fluid communication with the anterior chamber when the elongate member is implanted in the eye; and at least one polymeric film surrounding at least a portion of the elongate member, the film comprising a first drug delivery zone embedded with a first drug, wherein the first drug diffuses from the polymeric film over time into the eye at a first anatomical location. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)
-
Specification